Regulatory T cell proliferation inhibition

Regulatory T cell (Treg) proliferation inhibition is a complex biological process and therapeutic objective rather than a single molecular target such as a receptor or enzyme. Tregs, primarily defined by the expression of the transcription factor FOXP3 and the high-affinity IL-2 receptor CD25, are essential for maintaining immune homeostasis and preventing autoimmune reactions (Sakaguchi et al., 2008). In oncology, the expansion of Tregs within the tumor microenvironment often leads to potent immunosuppression, allowing tumors to evade detection and destruction by the immune system (Zou, 2006). Consequently, inhibiting the proliferation and functional activity of these cells is a major focus of cancer immunotherapy to bolster anti-tumor effector T cell responses (Curiel et al., 2004). This inhibitory effect can be achieved through various pharmacological means, including the use of checkpoint inhibitors like Ipilimumab, metabolic inhibitors, or low-dose cytotoxic agents like cyclophosphamide, which selectively target the Treg population (Curiel, 2007). Because this entry describes a physiological outcome resulting from the modulation of multiple distinct molecular targets, it is classified as a biological process rather than a discrete therapeutic molecule.

Other names

Treg proliferation inhibitionTreg suppressionInhibition of regulatory T-lymphocyte expansionRegulatory T-cell blockade

Inhibition of regulatory T cell (Treg) proliferation is achieved by blocking essential survival and expansion signals, such as the IL-2/CD25 pathway, or by modulating co-inhibitory and co-stimulatory receptors like CTLA-4, GITR, and OX40 that regulate Treg homeostasis.